Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ImmunoPET with 89Zr-DFO-REGN3767 in solid tumors
NCT04706715Phase 2Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jan 2022
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of 89Zr-DFO-REGN3767 in solid tumor, sponsored by University Medical Center Groningen. Started Jan 2022; status: active, not recruiting.
02
Drugs
89Zr-DFO-REGN3767
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04706715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04706715.